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ABSTRACT 
Colorectal cancer (CRC) is a major health concern and demands long-term efforts in 
developing strategies for screening and prevention. Over the past two decades, CRC has 
become a preventable disease. This remarkable revolution is a consequence of a better 
understanding of colorectal carcinogenesis, in particular, pre-symptomatic transitional 
lesions (i.e. adenomas) and their association with CRC occurrence and mortality. 
However, current therapy is unsatisfactory and necessitates the exploration of other 
approaches for the prevention and treatment of cancer. Plant based products have been 
recognized as preventive with regard to the development of colon cancer. Therefore, the 
potential chemopreventive use and mechanism of action of Lebanese natural product were 
evaluated. 
 
Towards this aim the antitumor activity of Onopordum cynarocephalum and Centaurea 
ainetensis has been studied using in vitro and in vivo models. In vitro, both crude extracts 
were non cytotoxic to normal intestinal cells and inhibited the proliferation of a host of 
colon cancer cells in a dose-dependent manner. Flow cytometric analysis showed that both 
extracts induced apoptosis. Extract induced apoptosis has been associated with the ability 
to induce the expression of p53 and p21 proteins and cause a significant increase in 
Bax/bcl-2 ratio. In vivo, both crude extracts injected intraperitoneally (i.p) prior to the 
subcutaneous (s.c) injection of the carcinogen 1, 2-dimethylhydrazine (DMH), reduced the 
number of tumors by an average of 65% at weeks 20 and 30. 
 
The activity of the C. ainetensis extract was attributed to Salograviolide A, a guaianolide-
type sesquiterpene lactone, which was isolated and identified through bio-guided 
fractionation. Salograviolide A was found to induce apoptotic cell death in colon cancer 
cells at non-cytotoxic concentrations to normal human intestinal cells.  
 
The mechanism of action of thymoquinone (TQ), the active component of Nigella sativa, 
was established in colon cancer cells using in vitro models.  By  the  use  of  N-acetyl  
cysteine (NAC), a radical scavenger, the direct involvement of reactive oxygen species 
(ROS) in TQ-induced apoptotic cells was established. TQ-increased phosphorylation 
states of the mitogen-activated protein kinases (MAPK) was linked to ROS generation. By 
using specific MAPK inhibitors, the two kinases JNK and ERK were found to possess 
pro-survival activities in TQ-induced apoptotic cell death.  
 
The analytical detection of TQ from spiked serum and its protein binding were evaluated. 
TQ was extracted from spiked serum by several extraction procedures prior to HPLC 
analysis. The average recovery from all the methods used was 2.5% proving the inability 
of conventional methods to analyze TQ from serum. Ultracentrifugation with 3K cut off 
filter and HPLC analysis were used to determine the percentage of binding of TQ to 
protein  serum.  More  than  98%  of  protein  binding  was  observed  as  of  0  min  of  TQ  
incubation with fetal bovine serum (FBS). Extensive binding was observed between TQ 
and two major plasma proteins, bovine serum albumin (BSA) and alpha-1-acid 
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glycoprotein (AGP). Incubation of TQ with BSA and AGP resulted in 94.5 ± 1.7 and 99.1 
± 0.1, percentage of binding, respectively. BSA and AGP's binding showed a differential 
effect on TQ's antiproliferative activity. While TQ bound to AGP retained its inhibitory 
effect as compared to TQ alone, its inhibitory effect was altered when bound to high 
concentration  of  BSA.  Using  mass  spectrometry  analysis,  TQ  was  confirmed  to  bind  
covalently to the free cysteine in position 34 and 147 of the amino acid sequence of BSA 
and AGP, respectively.  
 
The results of this work put at  the disposal for future development new plants with anti-
cancer activities and enhance the understanding of the pharmaceutical properties of TQ, a 
prerequisite for its future clinical development.   
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1. INTRODUCTION 
Cancer is classified as the second leading cause of death after cardiovascular diseases 
(Heron et al. 2009). Worldwide more than 20 million people are living with cancer, a fatal 
disease estimated to kill 9 million people by 2015 (Darwiche et al. 2007).  
The most frequent cancers are lung, colorectal (CRC), stomach, liver, and breast. CRC is 
the most common gastrointestinal cancer and a leading cause of death in the world. 
Although surgical excision is the best option for treatment, many patients who undergo 
therapeutic resection will develop tumor recurrences. Therefore, other approaches for the 
prevention and treatment of cancer are necessary. The fact that CRC is a stepwise process 
that takes 5-20 years from the time of initiation to adenoma formation, and another 5-15 
years until the beginning of the invasive stage offers a great opportunity for its prevention.  
 
Medicinal plants have been used by diverse cultures around the world and recognized as 
preventive with regard to the development of cancer (Lee et  al. 2006). In addition 
compelling evidence from epidemiological and experimental studies emphasizes the 
importance of compounds derived from plants to reduce the risk of cancer and inhibit the 
development and spread of tumors in experimental animals. Actually, more than 50% of 
drugs used during the last 20 years are directly or chemically altered natural products 
(Newman et al. 2007). For instance, vincristine and vinblastine are examples of plant-
derived compounds used against hematologic cancers such as multiple myeloma, acute 
lymphoblastic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma and Wilms’ tumor 
(Advani et  al. 2006; Cragg et  al. 2005; Kumar et  al. 2006; Darwiche et al. 2007). The 
advantage of plant derived compounds for cancer treatment is due to their health benefits 
and long use in folk medicine when substantial information have been collected on the 
safe use of plants, contrasted by the limitations of chemotherapeutic agents (Manson et al. 
2005). 
 
The utilization of plants is greatly affected by geography, climate and other major 
influencing  factors;  therefore,  the  higher  the  diversity  of  a  certain  region,  the  higher  the  
possibilities of finding plants with medicinal properties. The Mediterranean coast has 
varied microclimates with a wide diversity of plant species. Lebanon, a Mediterranean 
country, comprises more than a hundred plant species that are reported to have medicinal 
properties (Rouwayha 1983), have been used traditionally for hundreds of years 
(Rouwayha  1981), and are still commonly used. Some of the reported plants are Achilea 
falcate, Calendula officinalis, Centaurea ainetensis, Onopordum cynarocephalum, 
Ranunculus constantinopolitanus and Nigella sativa. Most of the aforementioned plants 
belong to the Astarecae/Compositae or Ranunculucae families known to have beneficial 
effects including anti-inflammatory, anti-diabetic, anti-rheumatic properties amongst 
others (www.ibsar.org). The scientific investigations on these plants are at different stages 
of development. While the reported data for most plants used in folk medicine is limited, 
the beneficial effects of N. sativa have been extensively studied and are already attributed 
to its quinone contents and specifically to thymoquinone (TQ). 
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Therefore,  as  part  of  the  ongoing  search  for  natural  products  against  colon  cancer  from  
traditionally used plants, two approaches have been followed: 1) unbiased approach to 
identify potential plant extracts against colon cancer based on screening studies, and 2) 
biased approach in which further mechanistic and analytical-investigations are carried on 
the well established anticancer compound TQ, derived from N. sativa, to gather more 
information that is needed before TQ can be further developed towards clinical 
applications. 
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2. REVIEW OF THE LITERATURE 
2.1. Colorectal Cancer 
 
2.1.1. Colorectal Cancer: Types and Molecular Genetics 
 
CRC is the most common gastrointestinal cancer and a leading cause of cancer deaths 
worldwide. Environmental as well as hereditary factors play a role in CRC development. 
For  instance,  sporadic  cancer,  those  cases  that  occur  in  individuals  over  age  50  without  
any identifiable predisposing factors, account for more than 75% of the various causes of 
CRC while the remaining are accounted for by familial incidence and inflammatory bowel 
diseases.   
 
Familial adenomatous polyposis (FAP) is an autosomal dominant colon cancer 
predisposition syndrome that appears upon the inheritance of a single copy of a mutant 
gene (Farinella et al. 2010; Kucherlapati et al. 2001). FAP syndrome is characterized by 
the appearance of hundreds to thousands of colonic polyps during the second and the third 
decade of life and is considered to be the least common type of colon cancer (Farinella et 
al. 2010; Kucherlapati et al. 2001). The gene responsible for FAP has been identified in 
1991 by Groden et al., (Groden et al. 1991) and termed the adenomatous polyposis coli 
(APC) gene.  
 
Hereditary non-polyposis colon cancer (HNPCC), also known as lynch syndrome, is 
another  autosomal  dominant  disorder  that  accounts  for  2-4%  of  the  cancer  cases  
(Jasperson et al. 2010; Kucherlapati et  al. 2001). Individuals with HNPCC are also at 
increased risk of other cancers, such as stomach, ovarian, small bowel, biliary, and kidney 
(Jasperson et al. 2010). Germline mutations in any of the following mismatch repair genes 
(mut l homolog 1 [MLH1], mut s homolog 2 [MSH2], mut s homolog 6 [MSH6], post-
meiotic segregation increased 1 [PMS1], post-meiotic segregation increased 2 [PMS2], 
and mut s homolog 3 [MSH3]) results in HNPCC (Neibergs et  al. 2002). Mutations in 
MLH1 and MSH2 are the most commonly observed mutations in HNPCC patients 
(Markowitz et al. 2009). 
 
Human sporadic colon cancer is thought to arise from spontaneous or induced somatic 
mutations in critical tumor suppressor genes or DNA mismatch repair genes (Nambiar et 
al. 2003). It has been proved that chromosomal instability or loss of heterozygosity (LOH) 
in tumor suppressor gene such as p53, APC, or deleted in colon cancer (DCC), or proto-
oncogenes such as Kras, c-erb, or c-myc are implicated in 80% of sporadic CRC (Neibergs 
et al. 2002; Rajamanickam et al. 2008; Zhou et al. 2004). Microsatellite instability (MSI) 
associated with mutations in DNA repair genes, on the other hand, has been identified in 
15-20 % of the cases (Mutch et al. 2007; Neibergs et al. 2002). 
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2.1.2. Morphological Changes in Colorectal Cancer 
 
The occurrence of cancer is associated with the incidence of pre-morphological alterations 
in apparently normal mucosa prior to the appearance of adenomatous polyps. The 
development of these morphological lesions is preceded and accompanied by a disorder of 
cell proliferation and differentiation. These lesions known as aberrant crypt foci (ACF) 
have been identified in the colonic mucosa of rodents exposed to colorectal carcinogens 
and  on  the  colonic  mucosa  of  patients  operated  on  for  cancer  or  benign  diseases  of  the  
large bowel (Bird 1987; Bird et al. 1989; Dias et al. 2010; Janakiram et al. 2010; Pretlow 
et al. 1991). ACF are distinguished from normal crypts by their darker staining, larger 
size, elliptical shape, and thicker epithelial lining. Although not all ACF have the potential 
to be transformed into adenomas and then carcinomas, these lesions by their 
morphological and molecular features are known to be precursors of colorectal cancer, 
extending hence the notion of adenoma-carcinoma sequence to ACF-adenoma-carcinoma 
(Cappell 2007). In fact, histological examination of ACF shows that these foci have 
variable features ranging from mild hyperplasia to dysplasia (Siu et  al. 1997; Siu et  al. 
1999). Only dysplastic ACF, a hallmark of malignant transformation, have the potential to 
develop  into  tumors.  The  progression  of  ACF  to  carcinoma  results  from  the  succession  
and accumulation of series of genetic alterations in colonic mucosa (Humphries and 
Wright 2008).  
 
Vogelstein et al. in 1988 have been the first to describe the stepwise process of colorectal 
carcinogenesis through which a series of genetic and epigenetic alterations lead to the 
development of carcinoma from the normal mucosa (Vogelstein et al. 1988). Substantial 
data suggest that carcinomas (malignant tumors) originate from adenomas (benign tumors) 
(Cunningham et  al. 2010; Sugarbaker et al. 1985). The evolution of colorectal cancer 
through the adenoma-carcinoma sequence can be simplified by highlighting the 
intervention of some of the most important markers: normal epithelium, upon loss or 
mutation of the APC gene, is transformed into hyper-proliferative epithelium. DNA 
methylation is responsible for the transformation of the hyper-proliferative epithelium into 
early adenoma. Due to the mutation of the K-ras gene and loss of DCC, the early adenoma 
is transformed into dysplastic adenoma, upon which the loss of p53 function results in the 
appearance of carcinoma. Though the adenoma-carcinoma sequence is a well-established 
concept  for  the  development  of  colorectal  cancer,  this,  however,  does  not  imply  that  all  
adenomas will transform into carcinomas since many of them may regress (Sillars-
Hardebol et al. 2010). In fact, the total accumulation of the genetic alterations, rather than 
their order according to a preferred sequence, is responsible for the determination of the 
tumor’s properties (Vogelstein et al. 1988).  
2.1.3. Treatment of Colon Cancer by Natural Anticancer Compounds 
 
Cancer chemoprevention is defined as the use of natural or synthetic compounds capable 
of inducing biological mechanisms necessary to preserve genomic fidelity (Hauser and 
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Jung 2008; Pan and Ho 2008b; Umar et  al. 2002). Such mechanisms include protection 
against mutagens/carcinogens through the inhibition of uptake, activation or via enhanced 
DNA repair/replication or apoptosis (Hauser et al. 2008; Sporn 1976). A potential 
chemopreventive agent has to be able to prevent, inhibit, or reverse carcinogenesis prior to 
the development of the invasive disease (Krzystyniak 2002; Pan and Ho 2008b). An ideal 
agent is one that 1) kills cancer cells while sparing normal ones, 2) has a defined 
mechanism of action, 3) is effective in multiple sites, 4) can be given orally, and 5) has 
low cost and high human acceptance.  
 
Several natural anticancer compounds are already on the market to treat different types of 
cancer. These agents belong to four different classes; the vinca alkaloids, the 
epipodophyllotoxins, the taxanes, and the camptothecin derivatives (Darwiche et al. 
2007). For instance, vincristine and vinblastine (vinca alkaloids) isolated from the plant 
Catharanthus roseus have been used for the treatment of hematologic cancers (Advani et 
al. 2006; Cragg and Newman 2005; Kumar et  al. 2006). Vindesine and vinorelbine are 
semisynthetic  analogues  of  vinca  alkaloids  that  show  less  toxicity  and  a  wider  range  of  
antitumor properties as compared to vincristine and vinblastine (Drawiche et al. 2007). 
The anti-cancer properties of podophyllotoxin, from the plant extract of Podophyllum 
peltatum, were discovered in 1942, but due to its high toxicity it has been discarded (You 
2005). In the mid 1960, semisynthetic analogues of podophyllotoxin, etoposide and 
teniposide, were discovered and are used for the treatment of lymphomas, non-Hodgkin’s 
lymphoma, Hodgkin’s lymphoma, acute leukemia, prostate, lung, testicular, bronchial and 
ovarian cancers (Bhutani et  al. 2006; Kelland 2005; You 2005). Paclitaxel, discovered 
from the Pacific Yew tree Taxus brevifolia, and its semisynthetic analogue docetaxel are 
the  most  commonly  used  taxanes,  a  class  of  alkaloids  that  possess  potent  anticancer  
activities. While paclitaxel is used for the treatment of ovarian, breast, prostate, urological 
and bladder cancers; docetaxel is used for the treatment of metastatic breast, ovarian, 
urothelial, lung, head and neck, gastric and prostate cancers (Kelland 2005; Lyseng-
Williamson and Fenton 2005; Yusuf et  al. 2003). 20(S)-camptothecin (CPT), isolated in 
1966 from the bark of the Chinese tree Camptotheca acuminate, was discarded in the 
1970s due to its severe toxicity despite its strong antitumor properties against 
gastrointestinal and urinary bladder tumors (Li et al. 2006; Wall et al. 1966). Other plant-
derived compounds such as flavopiridol, combretastatin A4, roscovitine, among others, 
are still under clinical trials and show promising anticancer results (Darwiche et al. 2007; 
Desai et al. 2008; Cragg and Newman 2005). 
Due to the fact that plants are home to many secondary metabolites that may provide 
chemoprotection against cancer, they potentially represent an inexhaustible source for the 
discovery of new drugs. 
2.2. Lebanese Plants in Drug Discovery  
Lebanon comprises more than 83 plant families with more than 2500 species distributed 
along its relatively small geographical area. More than hundred plant species used 
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traditionally are still commonly used to promote health (Rouwayha 1981; Rouwayha 
1983). However, the scientific studies that evaluate the activities of the Lebanese plants 
used  in  folk  medicine  are  limited.  In  an  effort  to  study  the  folk  use  of  these  plants,  the  
Nature Conservation Center for Sustainable Futures (IBSAR) at the American University 
of Beirut has set forth to conduct a thorough investigation to prove scientifically their use 
against diseases such as cancer. Towards this end, a screening program has been initiated 
since 2002 and a total of 110 crude extracts have been tested for their antiproliferative 
potential and cytotoxicity effects in a panel of normal and cancer cells using two 
bioassays, namely cell proliferation and cytotoxicity. The selection criteria have been pre-
defined as the potential extract has to inhibit the proliferation of cancer cells by more than 
50% without being toxic to normal cells. Based on the selection criteria cited previously, 
several plant extracts with potent and selective bioactivities against cancer cells versus 
normal cells have been identified among which are the crude extracts from O. 
cynarocephalum and C. ainetensis. On the other hand, N. sativa, used in Lebanese folk 
medicine, has been extensively studied. In fact, several studies have shown that N. sativa 
plant and its active constituent TQ have chemopreventive effect against colon cancer using 
both in vitro and in vivo models.  
2.2.1. O. cynarocephalum Boiss. & Blanche  
 
O. cynarocephalum (Fig. 1a), a species of Onopordum, belongs to the Compositae family, 
which comprise about 40 species distributed throughout the Mediterranean and semiarid 
areas of Eurasia and North Africa (Rees et al. 1999).   
Onopordum is an early Latin name given to a group of thistles. The name is derived from 
the Greek ‘’onos’’ which means ass and ‘’porde’’ which means flatulence, due to the 
belief that the plant induces flatulence in donkeys. Cynarocephalum also known as 
kynaros akantha, kynara or kinara derived from the Greek describing a spiny plant; Latin 
cinara has been attributed for a kind of artichoke and for a native of the island of Cinara, 
in the Aegean Sea, now Zinara;-cephalum means headed; cynara headed.  
 
O. cynarocephalum, an endemic plant to Lebanon known in Arabic as Shawk, grows wild 
to 0.5-3 meters tall  on the mountain Hermon. The plant has an alternate leaf pattern and 
purple flowers. The flowering period of the plant is between May and July and its optimal 
growth necessitates a nutrient rich soil (http://www.ibsar.org/Research/Traditional 
Knowledge and Biotechnology/Plants/Onopordum cynarocephalum.html). Although O. 
cynarocephalum has been traditionally used in Lebanon for its antibacterial, haemostatic, 
and hypotensive properties as well as for the treatment of skin cancer, the reported 
scientific studies proving the folk use for this species are limited. However, other species 
from Onopordum genera have been found to exert several biological activities such as the 
inhibition of TNF-? and nitric oxide in murine endothelial cells (Strzelecka et al. 2005), 
the augmentation of the NK cell activity (Abuharfeil et al. 2000; Abuharfeil et al. 2001), 
and the ability to change the rhythmic system by adjusting heart rate activity (Cysarz et al. 
2000). The beneficial effects of Onopordum genera  are  due  to  the  presence  of  many  
secondary metabolites with flavonoids, lignans, and sesquiterpene lactones being the most 
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common constituents (Braca et  al. 1999; El-Moghazy et al. 2002; Cardonas et al. 1992; 
Lazari et al. 1998). 
2.2.2. C. ainetensis Boiss.  
C. ainetensis (Fig. 1b) is one of more than 500 species of the genus Centaurea (Asteraceae 
family) that are distributed around the Mediterranean area and West Asia (Mabberlay 
1997).  
 
C. ainetensis,  an  endemic  plant  to  Lebanon  known  in  Arabic  as  shawkil-dardar,  grows  
wild in specific areas such as sterile, stony, or bushy places. The plant, however, does not 
grow in rocky habitats. The plant has a short and erect stem and its flowering period falls 
between May and June (http://www.ibsar.org/Research/Traditional Knowledge and 
Biotechnology/Plants/Centaurea ainetensis.html). Centaurea species have been 
traditionally used for their therapeutic and curative properties specifically by acting as 
stimulants, diuretics, anti-rheumatics, antimicrobial, anti-inflammatory, anti-tumor and 
anti-diabetics. The wide range of activities observed in the use of Centaurea in folk 
medicine along with the availability of many species has attracted the attention of scientist 
to test their efficacy. C. ainetensis and other Centaurea species have been reported to 
induce biological activities such as antioxidant (Karamenderes et al. 2007), antimicrobial 
(Buruk et  al. 2006; Skliar et al. 2005), wound healing (Csupor et al. 2010), anti-tumor 
(Ghantous et al. 2008; Koukoulitsa et al. 2002), and anti-inflammatory properties (Al-
Saghir et al. 2009). 
2.2.3. N. sativa L. 
N. sativa (Fig. 1c) (Ranunculaceae) is an annual flowering plant widely grown in different 
parts of the world specifically in countries bordering the Mediterranean area, in Pakistan 
and in India. 
 
In English, N. sativa seeds are known as Black Seed, Black Caraway, Black Cumin, and 
Roman Coriander. It is referred to as Melanthion by Hippocrates and Dioscorides. In old 
Latin it is called Panacea meaning cure all, while in India and China it is called Kalonji 
and Hak Jung Chou, respectively (Aggarwal et al. 2008). In Arabic the seeds are known as 
Habbatul-Barakah, which translates directly to the seeds of blessing. This latter 
description comes from the fact that the seeds are mentioned in religious texts such as the 
Quran, Bible and Torah.  
The plant grows to 20-30 cm tall. The plant has finely divided leaves with usually pale 
blue and white coloured flowers. The fruit is a capsule made of several united follicles 
containing each numerous seeds.  
 
This plant has been used for centuries in many Middle Eastern and Indian countries for 
culinary and medicinal purposes (Ali and Blunden 2003; Marsik et al. 2005; Norwood et 
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al. 2006). The folk uses of this plant include treatment of headache, coughs, abdominal 
pain, diarrhaea, asthma, rheumatism and others. For the last three decades, this plant has 
been  the  focus  of  scientific  research  to  study  its  chemical  composition  as  well  as  its  
biological activities in vitro and in vivo. Numerous studies show a broad spectrum of the 
plant’s biological activities including anti-inflammatory (Ali and Blunden 2003; Landa et 
al. 2009), anti-diabetic (Benhaddou-Andaloussi et  al. 2010), anti-hypertensive (Dehkordi 
et al. 2008), anti-histaminic (Boskabady et al. 2007), along with significant anti-neoplastic 
properties (Ait Mbarek et al. 2007; Worthen et al. 1998). In addition, oral use of the seed 
in moderate amount in food has been found to be safe (Der Marderosian et al. 2005). 
Therefore, based on the above reported activities, development of black seed-derived 
compounds could be useful in modern medicine. 
2.3. Salograviolide A and Thymoquinone 
 
Salograviolide A. The reported activities of Centaurea species have been attributed to the 
presence of various types of sesquiterpene lactones (Al-Saghir et al. 2009; Koukoulitsa et 
al. 2002; Ghantous et al. 2008; Giordano et al. 1992). For instance, Solstitialin A and 
acetyl solstitialin, sesquiterpene lactones isolated from C. solstitialis and C. depressa, 
have been found to be the components responsible for the anti-nociceptive and anti-pyretic 
activities of these plants (Akkol et al. 2009).  
 
Sesquiterpene lactones isolated from C. pullata and C. deusta, have been found to exert 
antibacterial and antifungal activities (Djeddi et al. 2008; Karioti et al. 2002). 
Salograviolide A (Fig. 1d), a sesquiterpene lactone guaianolide, isolated from C. nicoli has 
been  found  to  possess  antifungal  properties  (Vajs et al. 1999). In addition, anti-
inflammatory and anti-skin cancer properties have been attributed to Salograviolide A 
isolated from C. ainetensis (Al-Saghir et al. 2009; Ghantous et al. 2008). 
 
Thymoquinone. The activities exerted by N. sativa have been attributed to its quinone 
content, specifically to TQ (C10H12O2) (Fig. 1e) (Ali and Blunden 2003). The therapeutic 
potential of TQ has been confirmed in cancer research. In vivo, TQ has been found to 
reduce tumor growth using DMH and xenograft models of human colon cancer (Gali-
Muhtasib et al. 2008a), prevents tumor angiogenesis in a xenograft model of human 
prostate cancer (Richards et  al. 2008), inhibits the incidence and multiplicity of 
benzo(a)pyrene (BP)-induced fore-stomach tumors (Badary et al. 1999) and 20-
methylcholanthrene (MCT)-induced fibrosarcoma tumors (Badary et  al. 2001). In vitro, 
the inhibitory effect of TQ against colon cancer cells (El-Mahdy et al. 2005; El-Najjar et 
al. 2010; Gali-Muhtasib et al. 2008b), lymphoblastic leukemia cells (Alhosin et al. 2010), 
laryngeal carcinoma cells (Richards et al. 2006; Womack et al. 2006), pancreatic cells 
(Chehl et al. 2009), and prostate cancer cells (Richards et al. 2008; Richards et al. 2006) is 
well established.  
 
Generally, in the process of drug discovery a potential lead compound has to undergo 
preclinical evaluation prior to clinical trials. This includes lead optimization, definition of 
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mechanism of action, animal toxicity, and determination of its absorption, distribution, 
metabolism and excretion (ADME). Once the ADME is defined, the compound enters the 
phase of drug development, production/formulation prior to clinical trials (Lee 2010). 
Even though a review of the literature has shown that TQ induces apoptotic cell death via 
p53-dependent (Gali-Muhtasib et  al. 2004), p53-independent (El-Mahdy et al. 2005; 
Roepke et al. 2007), and p73-dependent pathways (Alhosin et al. 2010); its exact 
mechanism of action is not yet fully elucidated. In addition, there are no reports on TQ’s 
analytical detection or ADME.  
To better delineate TQ’s pharmaceutical properties it is important to clarify the chemical 
and analytical properties of quinones, the family to which TQ belongs. 
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Figure 1. a) O. cynarocephalum, b) C. ainetensis, c) N. sativa,  d)  Salograviolide  A,   e)  
Thymoquinone. 
 
2.4. Chemistry of Quinones  
 
Quinones are an important class of molecules harbouring physiological and therapeutic 
effects. They have two properties that define their biological activities. The first is their 
ability to undergo one or two electron reduction and the second is their ability to undergo 
nucleophilic attack. The knowledge of the inherent chemical reactivity of quinones is 
relevant to understand their physiological and toxicological properties.  
 
2.4.1. Quinones Redox Cycle 
 
The mechanism of quinones cytotoxicity is attributed mainly to their ease of reduction and 
therefore their ability to act as oxidizing or dehydrogenating agents. In biological systems 
quinones can undergo one or two electron reduction by cellular reductases leading to the 
corresponding semiquinones or hydroquinones, respectively (Scheme 1).  
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Scheme 1. Illustration, using benzoquinone as an example, of one and two electron 
reduction yielding semiquinone and hydroquinone respectively. 
 
The one-electron reduction of quinones can be catalyzed by a number of enzymes, 
including microsomal NADPH cytochrome P450 reductase (P450R), microsomal NADH 
cytochrome b5 reductase (b5R), and mitochondrial NADH ubiquinone oxidoreductase 
(Holtz et al. 2003; Monks and Jones 2002; Yan et al. 2008). The semiquinone radical, 
formed by one electron reduction, gets oxidized under aerobic conditions to the initial 
quinone with the generation of superoxide anion radicals. In aqueous solutions the former 
radicals interact with molecular oxygen to give rise to hydrogen peroxide, which in the 
presence of iron forms toxic hydroxyl radicals to which the toxicity of quinones is 
attributed (Asche 2005; Kappus et al. 1986). Ample evidence proves that ROS production, 
by numerous anticancer agents, is responsible for apoptosis induction in cervical (Lin et 
al. 2008), pancreatic (Zhang et  al. 2008), gastric (Qian et al. 2008b), breast (Xiao et al. 
2008), colon (Pan et al. 2008a), and hematologic cancers (Feng et al. 2007). For instance 
one electron reduction of doxorubicin (Bartoszek and wolf 1992), tirapazamine (Chinje et 
al. 1999; Patterson et al. 1995; Patterson et al. 1997), indoloquinone (Bailey et al. 2001), 
and mitomycin (Belcourt et al. 1998; Cowen et al. 2003; Joseph et al. 1996; Wang et al. 
2007) leads to significant increase in their cytotoxicity against cancer.  
 
In addition to the one-electron reduction, quinones can undergo two-electron reduction 
catalysed by the cytosolic flavoenzymes NAD(P)H:quinone acceptor oxidoreductases 
(NQO). NQO1, also known as DT-diaphorase, is a well-studied NQO and is considered a 
distinctive flavoenzyme for three reasons. First, it displays a nonspecific reactivity 
towards NADH and NADPH and shows broad electron acceptor specificity, catalyzing the 
reduction of quinones and structurally related compounds. Second, it is strongly inhibited 
by the NAD(P)H competitive inhibitor dicumarol and other oral anticoagulants. Third, the 
most striking feature is its ability to catalyze the so-called “obligatory” two-electron 
transfers (Bianchet et al. 2004; Cadenas 1995). This obligatory 2-electron reduction 
competes with the one-electron reduction of quinones by enzymes such as P450R and 
protects cells against oxidative stress (Guo et al. 2008).  This  protection  is  the  result  of  
conversion of quinones to hydroquinones rather than semiquinones and ROS, which is 
generated by redox cycling of semiquinones in the presence of molecular oxygen 
(Bianchet et al. 2004; Kappus and Sies 1981; Tampo and Yonaha 1996). Three types of 
hydroquinones are formed by DT-diaphorase action, 1) redox-stable hydroquinones, 2) 
redox-labile hydroquinones that subsequently auto-oxidize with formation of ROS and 3) 
hydroquinones that readily rearrange to potent electrophiles participating in bio-alkylation 
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reactions (Cadenas 1995). The properties of the hydroquinone generated by DT-
diaphorase determine whether this reduction leads to the activation or deactivation of 
quinones.  
 
2.4.2. Quinones Nucleophilic Addition 
 
Quinones’s electrophilic character enables them to undergo nucleophilic attack, which 
may lead to either detoxification or enhanced toxicity (Scheme 2). In a biological system, 
such nucleophiles may be found as reactive side-groups of lysine, serine and cysteine 
(Magee 2000). However, the thiol group of glutathione (GSH) represents the first to be 
involved in the nucleophilic addition reaction with quinones. In fact, the first line of 
cellular defense is controlled by GSH, an active ROS scavenger and the most abundant 
non-protein antioxidant in the cell. Many quinones can be conjugated to the sulfhydryl 
group of GSH and this reductive addition represents their major route of elimination. 
Quinone-GSH conjugation is a detoxification reaction because of the more hydrophilic 
character of the formed adduct as compared to the parent quinone. This conjugation can 
occur either spontaneously via a reductive addition or is catalyzed by glutathione-S-
transferase leading to hydroquinone-glutathionyl conjugates (Buffinton et  al. 1989; 
Jakoby and Ziegler 1990). Yet, nucleophilic addition might lead to their enhanced toxicity. 
For instance, quinone-GSH conjugation can also contribute to compound toxicity. This is 
caused in some cases by the faster redox cycling of the glutathionyl conjugates compared 
to that of the parent quinone (Buffinton et al. 1989; Jakoby and Ziegler 1990; van Ommen 
et al. 1992).  Another  mechanism  of  toxicity  stems  from  the  significant  depletion  of  the  
reduced thiol form of glutathione by alkylation in the presence of high concentrations of 
quinones. Once the detoxification system is saturated by GSH depletion, cellular SH-
dependent proteins can be alkylated thereby causing irreversible changes and cell death 
(Buffinton et al. 1989; Jakoby and Ziegler 1990). The propensity of quinones to bind to 
nucleophilic functional groups commonly found on many cellular components, represents 
the most popular mechanistic theory underlying their toxicity. Mutation and/or protein 
dysfunction can result from the conjugation of quinones to proteins or DNA (Buffinton et 
al. 1989; Jakoby and Ziegler 1990).  
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Scheme 2. Illustration, using benzoquinone as an example, of the nucleophilic addition 
with formation of mono-,di-,tri-, and tetra-susbtitution. 
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2.4.3. Analytical Detection of Quinones 
 
A wide range of analytical methods has been reported for the determination of quinones in 
plants, pharmaceutical preparations, as well as in biological samples. Gas chromatography 
(GC) (Zuo et al. 2008), Raman microscopy (Beattie et al. 2007), high-performance liquid 
chromatography (HPLC) (Xue et  al. 2008), and mass spectrometry (MS) (Kang et al. 
2007) have been used for the identification and quantification of quinones. HPLC and 
HPLC/MS are the most frequently used methods.  
 
Sample cleanup procedures for quinones are usually performed using solid phase 
extraction (SPE), liquid-liquid extraction (LLE) or protein precipitation. Protein 
precipitation using methanol (MeOH), ethanol (EtOH), and acetonitrile (ACN) has been 
usually used to disrupt protein binding and remove interferences from biological samples. 
SPE, in addition to its use as a cleanup method, is performed to concentrate the samples.  
 
Detection methods such as UV (Fahmy et al. 2004; Qian et al. 2008a; Xue et al. 2008), 
chemiluminescence (Ahmed et al. 2007) and fluorescence (Azharuddin et al. 2007), have 
been combined to HPLC methods. Several quinones can be detected by 
chemiluminescence due to their ability to generate hydrogen peroxide and a fluorophore 
when subjected to UV irradiation, a property that allows their determination through a 
peroxyoxalate chemiluminescence reaction by mixing with aryloxalate (Ahmed et  al. 
2007). Also post column chemical reduction for the detection of the reduced form of the 
quinone using a catalyst reduced column and a MeOH-EtOH mobile phase as reductant 
have been used (Azharuddin et al. 2007).  
 
Mass spectrometry, in negative or positive ionisation mode, is often coupled to HPLC for 
the  identification  of  the  quinones.  Different  mass  analysers  are  used,  depending  on  the  
structures of the studied compounds, especially electrospray ionisation (ESI) and 
atmospheric pressure chemical ionisation (APCI) instruments such as triple-quadrupole 
and ion trap instruments, which enable tandem mass spectrometry (MS/MS) 
measurements.  
 
Despite the fact that many methods have been used, the identification and quantification of 
quinones is still challenging due to their high reactivity as fast redox cycling molecules as 
well as their potential of binding to hydroxyl, thiol, and amine groups. Therefore, efforts 
to establish efficient, accurate and precise procedures for their quantification are ongoing.  
 
Wherever the conventional analytical methods for studying quinones in biological samples 
have failed in their detection, other approaches such as the use of radiolabeled or 
isotopically labeled compounds have been adopted. 
 
Tracer compounds whether isotopic or radioactive are useful tools for measuring and 
understanding the metabolism and disposition of both endogenous molecules and drugs. 
This is true in the case of compounds that are unstable or require to be detected at low 
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concentrations. Several studies using labeled quinones have been conducted so far and 
have been instrumental in clarifying their metabolic fate and/or mode of action. This is 
true in the case of studying vitamin K1 whereby specific challenges for its analysis in 
plasma result from its low concentration, interference of plasma lipid components, and the 
sensitivity of the molecule to degradation by light and strong alkaline conditions. Between 
1972 and 1979, three attempts to measure vitamin K1 turnover in human subjects have 
been made by using [1’, 2’-3H2] vitamin K1. However, none of these studies has allowed 
the calculation of the body pool of vitamin K1 due to the absence of a suitable method for 
measuring vitamin K1 in plasma (Bjornsson et al. 1979; Shearer et al. 1972; Shearer et al. 
1974). Nearly 20 years later, Olson et al., succeeded to determine the total body vitamin 
K1 and its turnover in human subjects at two levels of vitamin K intake using tritiated 
vitamin  K1 (Olson et al. 2002). Another example involves the study done by Miao et al. 
(Miao et al. 2008) on ?-lapachone, a promising anticancer compound. While studying its 
in vitro metabolism in plasma and whole blood, the compound could not be detected with 
conventional  LC-MS.  The  use  of  14C ?-lapachone has allowed studying the metabolic 
profiling and determining the reason for the failure of its detection in blood using 
conventional analytical methods. Using LC-MS coupled to a radioisotope counting system 
it has been shown that ?-lapachone is extensively metabolized in whole blood under in 
vitro conditions and the enzymatic activity is located in red blood cells. By determining 
the percent of radioactivity present in protein pellet prepared from whole blood spiked 
with 14C ?-lapachone, it has been proved that covalent protein binding of ?-lapachone 
and/or its metabolites is a minor contributor in the failure of its detection in blood (Miao et 
al. 2008).  
 
 
2.5. Methods in Preclinical Cancer Research 
 
To assess the efficacy of chemopreventive agents, it is not feasible to use cancer incidence 
or large polyp prevention as a primary method for evaluation; however, surrogate markers 
of carcinogenesis, of biological or morphologic events, instead of the actual cancer can be 
more useful (Kelloff et al. 1994; Liou et al. 2010; Sillars-Hardebol et al. 2010). 
 
These markers have to 1) display variability of expression through the different stages of 
cancer progression, 2) be detectable early in the carcinogenesis process, and 3) be coupled 
to the occurrence of pre-cancer or cancer. The efficacy of the chemopreventive agents will 
be reflected by the degree of modulation exerted by the agent on this marker. Many 
promising surrogate endpoint biomarkers for CRC chemoprevention have been evaluated 
(Einspahr et al. 1997; Liou et  al. 2010). These biomarkers are classified into different 
categories (cellular, molecular, biochemical, genetic, and pathologic markers).   
 
2.5.1. Cellular and Molecular Markers in vitro 
 
Proliferation and Toxicity Assays. The potential inhibitory effect of chemopreventive 
agents on the proliferation of cancer cells can be determined using the MTT (method of 
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transcriptional and translational) assay (Lawnicka et  al. 2010; Zhou et al. 2010). In this 
method the ability of metabolically active cells to convert a tetrazolium salt, (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole), into a blue formazan 
product by dehydrogenases and reductases is measured. The conversion takes place only 
when the enzymes are active. The effectiveness of any agent to cause death or induce 
metabolic dysfunction is therefore deduced by comparing the amount of purple formazan 
produced by treated cells to untreated cells (Mosmann 1983). A decrease of the color in 
treated cells as compared to control is an indication of metabolic dysfunction and 
inhibitory effect due to treatments. To measure treatment induced-cell cytotoxicity, 
however, the cytotoxicity assay that assesses cell membrane integrity is used (Chen et al. 
2010; Momeny et al. 2008). Toxic compounds often compromise cell membrane integrity 
and result in the passage, to the outside of the cells, of substances that are normally 
sequestered inside the cells. Lactate dehydrogenase (LDH) is one of the most commonly 
measured molecules for the assessment of drug toxicity. In this assay the extent of LDH 
release is proportional to the red formazan product obtained via a coupled enzymatic assay 
of LDH and tetrazolium salt, the absorbance of which is recorded at 490nm (Decker and 
Lohmann-Matthes 1988). 
 
Cell Cycle Distribution, Apoptosis, and Molecular Markers. To determine the effect of 
treatment on the distribution of cells in the different phases (preG1, G0/G1, S, G2/M) of the 
cell cycle, flow cytometry analysis of DNA content stained with propidium iodide (PI) is 
used (Moore et  al. 1998). PI is a DNA intercalating agent that emits fluorescence upon 
excitation. This method has been used to determine if the inhibitory activity observed with 
the proliferation assay is associated with specific changes in the different phases of the cell 
cycle such as cell cycle arrest and/ or apoptosis. By comparing data from treated and non- 
treated cells, it is possible to define the mechanism by which the drug might be acting. 
While an increase in the G0/G1, S, or G2/M (Schonn et al. 2010; Xiong et al. 2010) phase 
implies that the drug inhibits cell proliferation by inducing cell cycle arrest, an increase in 
the preG1 phase implies apoptosis/necrotic induction (Qin et al. 2010; Tabata et al. 2009). 
Whereas apoptotic cell death is characterized by well-defined cytological and molecular 
events leading to DNA fragmentation; necrotic cell death results in rapid loss of 
membrane integrity and release of cell content such as LDH to the environment (Riss and 
Moravec 2004). 
 
In treatments where an increase in preG1 has  been  observed  with  PI  by  flow  cytometry  
analysis, other methods such as TUNEL (Terminal deoxynucleotidyl transferase dUTP 
nick end labeling) and M30 cytodeath assays can be applied to differentiate apoptotic from 
necrotic cell death. TUNEL enzyme catalyzes the addition of dUTPs that are secondarily 
labeled with a marker to the terminal end of the nucleic acid. Using flow cytometry, 
apoptotic-induced fragmented DNA is visualized by the increase of fluorescence in treated 
cells as compared to control untreated cells (Gavrieli et al. 1992; Negoescu et al. 1996). 
M30 cytodeath antibody allows the determination of early apoptotic events in single cells 
by its ability to bind specifically to a caspase cleavage site, apoptosis marker, within 
cytokeratin 18 that is not detected in native normal cells (Dionne et al. 2010). 
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To characterize the molecular basis of drug-induced cellular growth inhibition, western 
blot analysis is used to study changes in the expression of key cell cycle mediators known 
to accompany cell cycle arrest and apoptosis such as cyclin D1, cyclin B1, p53, p21, Bax 
and Bcl-2 (Hedstrom et al. 2009; Kim et al. 2006; Sherr and Roberts 1995; Stewart et al. 
1995; Taylor and Stark 2001; Yasuda et al. 2010). 
 
2.5.2. Pathologic Markers In Vivo 
 
Effectiveness of Animal Models for Colon Cancer. The stepwise progression of human 
CRC may take from one to three decades from the time of initiation until the beginning of 
the invasive stage. Therefore, to study human CRC, animal models have to be used. The 
ideal animal model should have exactly the same histology, morphology and anatomy of 
human colonic neoplasms. However, based on a review of the available CRC models such 
an ideal animal model does not exist. On the other hand, some of the models approximate 
many of the characteristics of human colonic carcinogenesis; therefore, they can be used 
for clarification of the mechanisms of colorectal carcinogenesis and prevention of the 
occurrence of colorectal cancer (Femia et al. 2010; Kobaek-Larsen et al. 2000; Mori et al. 
2004). 
 
DMH and its metabolites are frequently used to study CRC in animal models for they 
induce colonic tumors with a similar histology, morphology and anatomy to human 
colonic neoplasms (Femia et al. 2010; Ma et al. 2002; Ma et  al. 2004). Human colon 
cancer, however, differs from DMH-induced colon cancer by the metastatic potential of 
human adenocarcinomas. While half of the patients with colon cancer end up with 
lymphatic or liver metastasis, DMH-induced adenocarcinomas have little potential for 
metastasis (Dionne et al. 1965; Haase et al. 1973). 
 
Description of the DMH Model. In order to become a carcinogen, DMH must be 
activated by a series of metabolic transformations leading to a number of intermediates 
(Fiala 1977).  In  the  first  step  DMH  is  oxidized  to  azomethane,  which  after  another  
oxidation forms azoxymethane (AOM). Hydroxylation of the latter molecule forms 
methylazoxymethanol (MAM), which in the final step is converted to formalin and 
methyldiazonium ion, alkylating agents of DNA, RNA, and protein principally in the 
colon, liver, and kidneys (Kobaek-Larsen et al. 2000). 
 
Activation of AOM and MAM has been attributed to the effect of the alcohol-inducible 
cytochrome P-450 isoform, CYP2E1 (Sohn et al. 2001). The specificity of DMH to 
colonic mucosa is probably the consequence of the relative stability of its metabolite 
MAM (Nagasawa et al. 1972). With a half-life of approximately 12h, MAM has sufficient 
time to distribute to the colon (Feinberg and Zedeck 1980). 
 
The fact that CRC is a stepwise process where dysplastic ACF transform to adenomas, the 
majority of which transform to adenocarcinomas, makes the use of these intermediates 
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potential pathologic biomarkers for CRC (Cai et al. 2010; O’Brien et al. 1990; 
Velmurugan et al. 2008). 
 
The DMH model has been widely used to assess the potency of chemopreventive agents 
on  ACF (initiation),  adenomas  (promotion),  and  adenocarcinomas  (progression)  of  CRC 
development. For instance, the DMH model has been used to study the chemopreventive 
effect of etoricoxib (a cyclooxygenase inhibitor), astaxanthin (a carotenoid), Yogurt, and 
refecoxib. While the reported chemopreventive effects of etoricoxib and astaxanthin have 
been due to their significant inhibition of DMH-induced ACF (Prabhu et al. 2009; Sharma 
et al. 2010), Yogurt and rofecoxib, however, have been found to exert their effects on 
adenomas and adenocarcinomas formation (progression and promotion stage of CRC) (De 
Moreno de Leblanc and Perdigon 2004; Noguera Aguilar et al. 2005). 
 
 
2.6. Protein-Drug Binding in Plasma 
 
Protein binding is generally referred to as the reversible binding of drugs to plasma 
components. Once a drug reaches the blood circulation after intravenous injection or 
absorption, it interacts with plasma proteins via two different ways: either adsorption to 
the protein surface or more rarely by covalent binding (Barnaby and Bottacini 2004). 
Human plasma contains more than 100 proteins among which six are able to bind drugs: 
human  serum  albumin  (HSA),  AGP,  lipoproteins  (VLDL,  HDL  and  LDL,  and  
immunoglobulin G (Barnaby and Bottacini 2004). 
 
HSA is the most abundant protein in plasma whereby it represents more than 60% of all 
plasma proteins. HSA has 17 disulfide bridges and one free cysteine (Cys-34). The free 
thiol of the cysteine residue is redox active capable of thiolation and nitrosylation, and 
accounts for more than 80% of the thiols in plasma. HSA binds to many endogenous and 
exogenous compounds and participates in different processes such as drug delivery, 
detoxification, and antioxidant properties (Quinlan et al. 2005).  
 
AGP, the second major protein in plasma, has very high carbohydrate content of 45%. 
AGP is considered as a major member of the positive acute phase protein family; while its 
concentration remains stable in physiological conditions, it increases several-fold during 
acute-phase reactions. AGP is encoded by two genes that differ by 22 substitutions 
resulting in two different polypeptides (Fournier et  al. 2000). The two isoforms differ 
mainly  by  the  presence  of  an  additional  cysteine  in  position  147  of  the  amino  acid  
sequence in one of the isoforms (Schmid et al. 1973). AGP binds to basic drugs and small 
molecules such as steroid hormones. Although AGP plays a key role in binding basic 
drugs, it binds to neutral and acidic drugs but to a lesser extent (Banker et al. 2008; Israili 
and Dayton 2001). In addition, AGP can induce various immunomodulating effects 
(Fournier et al. 2000). In plasma the concentration of AGP is 100 fold lower than that of 
albumin (Barnaby and Bottacini 2004). While HSA is considered as a high capacity low 
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affinity protein, AGP on the other hand is a low capacity high affinity protein (Barnaby 
and Bottacini 2004). 
 
In addition to plasma proteins, drugs can bind to tissue proteins. The reversible binding of 
the drug to plasma components results in an equilibrium between the concentration of 
bound and unbound drug (Longmei et al. 2005). Binding of drugs to proteins has serious 
implications since it can affect the therapeutic, pharmacodynamic, as well as the 
toxicologic actions of the drug. This can be explained by the fact that only unbound drug 
reaches the site of action, and tightly bound drugs tend to distribute in a smaller body 
volume and cause a delay of their elimination etc., therefore, the determination of the 
unbound concentrations of the drug is important for the determination of its 
pharmacokinetic (PK) and pharmacodynamic (PD) studies (Vallner 1977). The desire to 
predict ADME parameters to assist in early PK/PD modeling in the drug discovery 
process places an increased demand for protein and tissue binding studies (De Buck et al. 
2007; McGinnity et al. 2007). 
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3. AIMS OF THE STUDY  
 
The aim of this thesis is to discover bioactive natural products from Lebanese plants used 
in folk medicine as candidates for future clinical development against colon cancer. 
Molecular and cellular biology as well as analytical chromatographic studies have been 
performed to achieve the goal. 
 
Specific aims of the study: 
 
1. Evaluate the anticancer activities of O. cynarocephalum and C. ainetensis selected 
in screening studies, using in vitro and in vivo models for colon cancer (I, II). 
 
2. Investigate the in vitro mechanism  of  action  of  the  anticancer  molecule  TQ,  the  
active constituent in Nigella sativa, for further preclinical evaluation (III). 
 
3. Investigate the analytical detection of TQ in biological matrices as well as its 
binding to plasma proteins, necessary for future kinetic studies (IV).
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4. MATERIALS AND METHODS 
 
A thorough description of the materials and methods is presented in the original 
publications (I-IV). 
 
4.1. Reagents 
 
Cell culture reagents such as media, serum, etc. were obtained from Gibco BRL Life 
Technologies (Gaithersburg, Maryland, US). Other kits and reagents were purchased from 
Promega Corp (Madison, Wisconsin, US), Molecular Probes (Eugene, Oregon, US), 
Roche Diagnostics Corporation (Mannheim, Germany), Bio-Rad (Hercules, California, 
US) and Amersham Pharmacia Biotech (Amersham, England). Antibodies and inhibitors 
were  from  Santa-Cruz  (Santa-Cruz,  California,  US),  Biogenesis  (Poole,  UK),  Cell  
Signaling  Technology  (Beverly,  US),  Acros  Organics  (New  Jersey,  US)  and  Sigma  
Chemical  Company  (St.  Louis,  Missouri,  US).  TQ  was  purchased  from  MP  Biomedical  
(Strasbourg, France). LC solvents were HPLC grade from Rathburn (Walkerburn, UK). 
C18 PrepSep solid phase extraction (SPE) cartridges were purchased from Fisher Scientific 
(Pittsburgh, Pennsylvania, US). Amicon Ultra centrifugal filters with 3K cut off were 
obtained from Millipore (Carrigtwohill, Co. Cork, Ireland). 
 
4.2. Animal Cells and Plant Material  
 
Normal mouse intestinal ModeK cells were kindly provided by Prof. F. Homaidan 
(Department of Human Morphology, American University of Beirut, Lebanon). FHs74Int 
normal  human intestinal  epithelial  cells,  HCT-116 and  HT-29 human colon  cancer  cells  
were kindly provided by Prof. R. Schneider-Stock (Experimental Tumor pathology, 
Institute for Pathology, University Erlangen-Nuremberg, Erlangen, Germany). DLD-1 
cells were kindly provided by Prof. M. Ocker (Institute for Surgical Research, Philipps 
University Marburg, Marburg, Germany). O. cynarocephalum and C. ainetensis were 
collected from Lebanon and voucher specimens were deposited in the George Post 
Herbarium at the American University of Beirut (Beirut, Lebanon). 
 
4.3. Animal Experiments 
 
In studies I and II, 6-9 weeks old, female Balb/c mice were randomly distributed to 
treatment and control groups. During the toxicity study, crude extracts (I, II) were given 
i.p. to the mice for 10 consecutive days and toxicity signs such as death and body weight 
loss were monitored. For the long term experiment (30 weeks), control groups were 
injected (i.p.) with 0.9% sodium chloride, crude water extracts (I, II), or (s.c.) with 20 
mg/kg mouse body weight of DMH. Treatment groups were injected i.p. with the crude 
extract 15 min prior to DMH injection. The injections were done once a week. At week 
10, mice were sacrificed and colon tissues were processed and stained with Schiff's 
reagent. ACF were examined and their size and location recorded using fluorescent 
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microscopy. At weeks 20 and 30, colon tissues were processed and visible tumors were 
counted using an optical microscope.  
For TQ analysis in spiked serum (IV), intact male Sprague-Dawley rats, average weight of 
250 g were used. The blood was collected by heart puncture into EDTA containing tubes, 
centrifuged  (3000 rpm, 4 °C, 5 min), and serum aliquots were stored in plastic tubes at  
-20 °C until used. Handling the animals was conducted using a protocol approved by the 
Institutional Animal Care and Use Committee of the American University of Beirut. 
 
4.4. Methods  
 
4.4.1. Crude Extract Preparation, Fractionation, Isolation and Molecular   
          Identification Procedures  
 
Water extraction. Twenty grams of air-dried ground material (I, II) was placed in 160 ml 
of boiled distilled water [material/solvent concentration (w/v) of 1:8] and shook for 20 
min using an incubator shaker. The resulting solution was then filtered through Whatman 
No. 2 filter paper and stored at -20 ºC until used in well-sealed 150-ml bottles covered 
with aluminium foil for the bioassays. Crude extracts were filter sterilized using 0.2?m 
non-pyrogenic sterile-R filters before treatment. 
 
Methanolic extraction and fractionation. Plant material was soaked in MeOH at a 1:10 
ratio (w/v) and incubated on a shaker at 20 °C for 16 h. After extraction the extract was 
filtered and separated into residue labeled as (R-I) and a filtrate labeled as “I” which was 
named as "MeOH crude extract". The residue labeled as R-I was then soaked in EtOAc at 
10 to 1 ratio (10:1 w/v) and filtered to give “I.1”. 
Concentrated sulfuric acid solution was added to the crude extract “I” until the pH reached 
2 after which a mixture of chloroform (CHCl3): water (2:1 v/v) was added. 
The chloroform phase was collected and labeled as “I.2”. The pH of the aqueous layer was 
adjusted to 10 by adding conc. ammonia solution; the obtained mixture was then 
suspended in a CHCl3:MeOH mixture (3:1 v/v), separated into organic and aqueous layers 
and  labeled “I.3” and “I.4”, respectively. All fractions were dried in vacuo at 40 °C, the 
residues were dissolved in minimal amounts (0.1-1ml) of EtOH.  
Only fraction I.2, which exhibited anticancer activity was concentrated in vacuo at 40 °C. 
The residue (0.48 g) was applied to a chromatographic column consisting of 150 g of 
silica gel (0.035-0.07 mm and 6 nm pore diameter). A gradient elution was performed 
using petroleum ether:CHCl3:EtOAc (2:2:1), followed by petroleum ether:CHCl3:EtOAc 
(1:3:1) (500 ml), CHCl3:EtOAc (3:2) (250 ml), CHCl3:EtOAc:MeOH (3:3:1) (525 ml), 
CHCl3:EtOAC:MeOH (3:3:2) (900 ml), CHCL3:MeOH (3:2) (750 ml) and MeOH 
successively. The anticancer activity was found in sub-fraction I.2.2, a fraction eluted with 
CHCl3:EtOAC:MeOH (3:3:1). Normal phase SPE cartridges (Alltech, silica, 200 mg/4.0 
ml, 50/P; particle size 50 ?m and average pore size 60 °A) were used to purify the active 
subfraction (I.2.2). Gradient elution consisting of CH2Cl2 (20  ml),  CHCl3 (20  ml),  and  
MeOH (10 ml) was used and the pure compound was eluted with CHCl3 (20 ml). 
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Spectroscopic Measurements. 1D and 2D NMR spectra were recorded using deuterated 
chloroform (CDCl3) (Acros Organics, New Jersey, US) by a Bruker 300 MHz 
spectrometer (Bruker, Bremen, Germany). Chemical shifts were reported in ? (ppm) 
values  relative  to  TMS (Acros  Organics,  New Jersey,  US).  For  GC analysis,  a  Hewlett-
Packard 6890 gas chromatograph equipped with HP-5 capillary column was used (Fisher 
Scientific,  Pittsburgh,  Pennsylvania,  US).  The  carrier  gas  was  helium  and  the  flow  rate  
was 1ml/min. The column was heated from 35ºC to 290ºC and the maximum temperature 
was 350°C. Results were recorded as percent of total peak areas. The mass spectrometer 
employed  in  the  GC-MS  analysis  was  a  Hewlett  Packard  7972  series  mass  selective  
detector in the electron impact (EI) ionization mode (70 eV) (Fisher Scientific, Pittsburgh, 
Pennsylvania, US). FTIR spectra were recorded on a Nicolet AVATAR 360 FTIR 
spectrometer. UV-Vis spectra were measured in MeOH using a JASCO V-570 
UV/VIS/NIR spectrophotometer (JASCO Inc., US).  
 
4.4.2. Cell Culture  
 
Colon cancer and normal intestinal cells, listed in table 1, were maintained at 37 ºC in a 
humidified  atmosphere  of  5  %  CO2, 95 % air, supplemented with 1 % penicillin–
streptomycin (100 U/ml), and 10 % fetal bovine serum (FBS). In all experiments (I, II, III, 
IV) except ELISA assays (III), cells were seeded at 105 cells/ml and exposed at 40–50 % 
confluency to different concentrations of crude extracts of O. cynarocephalum (I), C. 
ainetensis and its fractions { I.1-I.4, I.2.1-I.2.6 } (II), Salograviolide A (II), and TQ (III, 
IV). For experiments involving inhibitors (III), cells were pre-treated with 5 mM NAC for 
2 h, 50 µM PD98059 for 2 h, 20 µM SP600125 for 1.5 h or with 100 µM dicoumarol for 1 
h prior to TQ. For experiments involving protein binding (IV), 6.6 µg/ml TQ was prepared 
in different concentrations of FBS {5, 10, 20, and 40 %}, BSA {30, 60,120, and 240 µM}, 
AGP {1.25, 2.5, 5, and 10 µM} and added to the cells after incubation for 30 min at 37 °C. 
TQ stock was prepared in MeOH (III)/DMSO (IV) and the final concentration of either 
vehicle on cells was less than 0.5 %. 
  
Table 1: list of all cancer and normal cells used in this study 
Colon cancer cells Publications 
HCT-116 p53+/+ I, II, III 
HCT-116 p53-/- II 
HT-29  I, III 
DLD-1 II, III, IV 
Lovo and Caco-2 III 
Normal intestinal cells Publications 
FHs74Int I, II, III 
Modek I 
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4.4.3. Cell Proliferation and Viability Assays 
 
Inhibition of cell proliferation was studied using the Cell Titer 96 non-radioactive cell 
proliferation kit, MTT (Promega Corporation, Madison, Wisconsin, US) in (I, II, III) and 
using a commercial colorimetric WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzenedisulfonate) cell proliferation assay (Roche Diagnostics GmbH, 
Mannheim, Germany) in (IV), according to the manufacturer's protocol. 
Briefly, colon cancer cells were plated in 96-well plates and treated with different 
concentrations  of  crude  extracts  (I,  II),  fractions  and  Salograviolide  A  (II),  TQ  in  the  
presence or absence of NAC, PD98059, SP600125, or dicoumarol for 24 h and 48 h (III), 
and TQ in the presence or absence of FBS, BSA or AGP for 6 h (IV).  
The CytoTox 96 (viability) assay was done 6 h (II) and 24 h (I, III) post-treatment using 
the CytoTox 96 non-radioactive cytotoxicity kit (Promega Corporation, Madison, 
Wisconsin, US). The absorbance was recorded at 550, 440 and 490 nm for MTT, WST-1 
and cytotox assay, respectively.  
 
4.4.4. Cell Cycle Analysis Using Flow Cytometry 
  
PI  staining  was  used  to  follow  the  distribution  of  cells  in  the  different  phases  (preG1, 
G0/G1, S, G2/M) of cell cycle upon treatment. Cells were seeded, treated, and collected  
24 h (I, II, III) and 48 h (III) post-treatment. Collected cells were washed with phosphate 
buffer saline (PBS) and fixed in 70% EtOH at least for 2 h at -20 ºC. After fixation 
washed cells were stained with PI and analyzed by fluorescence activated cell sorting 
FACScan flow cytometer (Becton Dickinson, US). The percentage of cells in the different 
phases was then determined using the Cell Quest Histogram analysis program. Cells that 
were less intensely stained than G1 cells in flow cytometric histograms were considered as 
apoptotic cells and marked as preG1. 
 
4.4.5. Evaluation of Apoptosis 
  
Apoptotic cell death was measured in treated cells 24 h post treatment by TUNEL assay (I, 
II) and 24 h/48 h post-treatment by M30 cytodeath assay (III), mitochondrial membrane 
potential analysis DiOC6 (III) and caspase-3 activity (III). The TUNEL assay measures 
the extent of DNA fragmentation by the Terminal deoxy-transferase (tdT)-mediated dUTP 
nick end-labeling technique. The M30 cytodeath antibody recognizes a specific caspase 
cleavage site with cytokeratine 18 that is not detected in native cells. The 
dihesiloxalocarbocyanine Iodide (DiOC6 (3)) measures the loss in mitochondrial potential 
due to apoptosis induction. Collected and stained cells were analyzed using FACScan flow 
cytometer (I, II, III) or by fluorescent microscope Leica DM6000B using 20-fold 
magnification (III). Caspase-3/7 activity assay, which measures caspase 3/7 activation-
associated apoptosis, was determined in cell lysates and the luminescence was measured 
by a microplate reader (TECAN GENious, Switzerland). 
 
 
 
 
 
 
34
4.4.6. Intracellular ROS Generation by DCFH 
 
Oxidative stress was examined in study III by measuring the level of ROS using 2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA), a molecule that passively diffuses into 
the cells and is cleaved and oxidized in the intracellular environment to the green 
fluorescence emitting compound, 2’,7’-dichlorofluorescein (DCF). Cells were treated at 
50% confluency with TQ in the presence and absence of NAC then incubated with DCFH-
DA for 30 min in the dark. ROS generation was determined by flow cytometric analysis. 
 
4.4.7. Western Blot 
 
In studies I, II and III, colon cancer cells were treated as described earlier and cellular 
protein extracts were prepared in 2X SDS-lysis buffer. Protein quantification was done 
using the DC Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, California, US) 
according to the manufacturer’s protocol. Equal amount of protein lysates, prepared in  
10 % ?-mercaptoethanol and 2X sample buffer containing bromophenol blue, were placed 
on 12% SDS–PAGE for 2 h at 90 V then transferred onto polyvinylidene difluoride 
(PVDF) membrane (Amersham, Arlington, Illinois, US) in transfer buffer under 30 volts 
overnight at 4 ºC. Each membrane was immunoblotted with appropriate primary and 
secondary antibodies, reacted with enhanced chemiluminescence reagent, and exposed to 
X-ray films for different time periods. Membranes were re-probed with GAPDH or actin 
to ensure equal loading. Band quantification was performed using the Labworks software 
(Ultraviolet Products, Upland, Canada). 
 
4.4.8. Cellular Activation of MAPK Signaling 
 
In study III cells were plated at 1.5 x 105 cells/ml in 96-well plates and after overnight 
starvation in serum-free medium treated with TQ. Cells were fixed and after 30 min the 
relative extent of target protein phosphorylation (p-ERK, p-JNK, p-p38) was determined 
using CASE kits according to the manufacturer’s procedures (SuperArray Bioscience 
Corporation, Frederick, Maryland, US). 
 
4.4.9. High Performance Liquid Chromatography (HPLC) 
 
In all the experiments (IV) rat serum was diluted (1:1) with PBS and spiked with TQ to 
yield a final concentration of 10 µg/ml. Spiked samples were subjected to several 
extraction methods (a-c) prior to HPLC analysis as follows: a) C18 PrepSep SPE followed 
by drying under a stream of nitrogen, b) LLE step with different ratios of EtOAc (1:1, 
1:1.5, 1:2, and 1:3, v/v) followed by centrifugation (14000 g, 4 °C, 10 min), c) protein 
precipitation with different ratios (1:1, 1:2, 1:4, v/v) of MeOH and ACN followed by 
centrifugation at 14000 g for 10 min. For quantification, stock solutions of TQ were 
prepared in ACN and standard calibration curves of the stock were generated by serial 
dilution using ACN or PBS (IV). The analysis was conducted on an Agilent Technologies 
1100 series instrument (Waldbronn, Germany), comprising a vacuum degaser, an 
 
 
 
 
35
autosampler, a binary pump, and a diode array detector. Chromatographic separation was 
performed on a Phenomenex (Torrance, California, US) C18 column (25  ×  4.6  mm I.D.)  
with 5?m packing material. Samples were eluted using an isocratic mobile phase of water: 
ACN (45:55% v/v) at a flow rate of 1 ml/min. Diode array detector signal was recorded at 
254 nm and the injection volume was 20 µl. The chromatographic data were acquired and 
analyzed using Agilent Chemstation software package.  
 
4.4.10. Protein-Binding Studies 
 
To determine the percentage of protein binding (IV), FBS and 10 % FBS (diluted with 
DMEM high glucose as used in cell culture experiments) were spiked with TQ to yield a 
final concentration of 3.3 µg/ml, 6.6 µg/ml and 13.2 µg/ml. Samples were incubated at  
37 °C and 400 µl were collected at 0, 5, 10, 15, 30, 60, 120, 240, and 360 min. Further 
binding experiments were performed using BSA and AGP. The concentrations of BSA 
and AGP in serum are approximately 40 mg/ml (600 µM) and 0.97 mg/ml (25 µM), 
respectively. Therefore, BSA and AGP at concentrations corresponding to 10 % FBS were 
incubated at 37 °C with TQ 6.6 µg/ml for 30 min prior to analysis. Samples were filtered 
using Amicon Ultra with 3K cut off by centrifugation at 14000 g for 30 min. The filtrates 
were then analyzed by HPLC and the percentage of binding was calculated using the 
following equation: [% binding= (Total-free)/Total *100]. TQ recovery from standard 
subjected to the same procedure was 91.3 ± 0.6 %, therefore no correction was made while 
calculating the percentage of binding.  
 
4.4.11. Amino Acid Sequence Synthesis, Purification, and Binding Assay  
 
TQ binding to free thiol from BSA and AGP was tested using synthesized sequences 
corresponding to the region containing the free thiol. While one sequence YLQQCPFED 
was synthesized for BSA, two variants - CLCIP and CLAIP - were synthesized for AGP. 
The major difference between the two AGP isoforms is the presence of an additional free 
cysteine in one isoform while the other isoform had an arginine residue instead. The first 
cysteine from each AGP sequence was alkylated and consequently not available for 
binding. The position of free cysteine was determined by using the protein data bank.  
The selected peptides were synthesized on an ACT-396 peptide synthesizer at a 0.2 mmol 
scale, using Rink amide resin, double coupling standard fluorenylmethyloxycarbonyl 
FMOC-chemistry  protocols  (6  fold  excesses  of  protected  amino  acids),  TBTU/HOBT as  
coupling reagent, 20 % piperidine in NMP for FMOC de-protection and mixture of 
phenol:H2O:EDT:thioanisol:TFA = 1.5:1:1:1:10 for 2 h at room temperature for final 
cleavage/de-protection. After cleavage/de-protection, crude peptides were precipitated 
with ice-cold diethylether, filtered, dried and analyzed by RP-HPLC (HP 1050 series 
chromatography, Supelco Discovery C18 column (15 cm x 4.6 mm, 5 ?m), ? = 220 nm, 
linear gradient from 0 to 70% B in 40 min; A – 0.1% TFA, B – 0.1% TFA in 80% ACN). 
TQ was then incubated with the sequence for 30 min at 37 °C after which covalent 
binding was detected by mass spectrometry. 
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4.4.12. Mass Spectrometry Analysis 
 
Waters (Micromass) QTOF micro mass spectrometer (Manchester, UK) with electrospray 
ion source was used in positive ion mode to study TQ binding to the synthesized 
sequences. Samples were dissolved in 50/50 H2O/MeOH containing 0.1% formic acid. 
Samples were injected at a flow rate of 10 µl/min. The desolvation temperature was  
75 °C and source temperature was set to 150 °C. Capillary voltage was 3 kV, sample cone 
was 15.0 V, and extraction cone was 2.0 V. Cone gas and desolvation gas flow was set to 
200 l/hr.  
 
 
4.4.13. Statistical Analysis 
 
Results are expressed as mean ± standard error (SE) (I, II, IV) and mean ± standard 
deviation (SD) (III). Statistical analysis was performed using SPSS Student Version 11.0 
Software Package (I, II, III) and SYSTAT VERSION 12 Software Package (IV).  
Comparisons between the different groups were evaluated using ANOVA followed by 
Dunnett test (I, II), and one-tailed Student’s t-test (III, IV). The level of significance was 
set at 0.05. For all tests, p < 0.05 was considered as significant. 
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5. RESULTS 
 
The main findings are described in the section below and more detailed results can be 
found in the original publications (I-IV). 
 
5.1. Anticancer Properties of O. cynarocephalum and C. ainetensis (I, II) 
 
The inhibitory effect of the crude extract of O. cynarocephalum and C. ainetensis has been 
tested in vitro against a panel of colon cancer and normal intestinal cells using MTT-
Cytotox assays. Both extracts inhibited the proliferation of colon cancer cells in a 
concentration-dependent manner (Fig. 2a) and were more cytotoxic to cancer cells than to 
normal cells. PI staining of DNA content showed that the inhibitory effect observed with 
both extracts was due to apoptosis induction as evident by the increase in the percentage 
of fragmented DNA in the preG1 phase  of  the  cell  cycle  (Fig.  2b).  The  TUNEL  assay,  
which  measures  the  extent  of  DNA  fragmentation  by  the Terminal deoxy-transferase 
(tdT)-mediated dUTP nick end-labeling technique, was used to confirm the nature of cell 
death. Extract-treated cells underwent a significant amount of apoptosis as compared to 
untreated control cells. The percentage of TUNEL positive cells correlated well with the 
increase in preG1 phase observed by flow cytometry analysis, thus confirming apoptosis 
induction. 
 
To further investigate the mechanism of extract-induced apoptosis, changes in the 
expression of key cell cycle and apoptotic mediators such as cyclin B1, p21, p53, Bax, and 
Bcl-2 were monitored in HCT-116 treated cells by western blot. 
An increase in the expression of p53, p21 and Bax/bcl-2 ratio along with a decrease in 
cyclin B1 expression was observed upon treatment with both extracts (Fig. 2c).  
The tumor suppressor gene p53 is known to protect mammals from neoplasia by inducing 
cell cycle arrest, DNA repair, and apoptosis through activation of its downstream effectors 
p21, Gadd45 and Bax. This activation occurs in a response to a variety of stresses such as 
DNA damage, hypoxia and chemotherapeutic drugs (Hedstrom et al. 2009; Kim et al. 
2006; Taylor and Stark 2001). Up-regulation of Bax and down-regulation of Bcl-2 favors 
the pro-apoptotic over the anti-apoptotic response in cells, leading to programmed cell 
death. Cyclin B1 rises during the G2/M phase of the cell cycle and peaks into mitosis and 
its destruction is fundamental for mitotic exit and cytokinesis (Takizawa and Morgan 
2000; Yasuda et al. 2010). Extract-mediated cell cycle arrest and apoptosis correlated well 
with their ability to differentially modulate the expression of components of the signaling 
pathways involved in cell cycle arrest and apoptosis.  
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Figure 2. Effect of crude extracts of O. cynarocephalum and C. ainetensis on HCT-116   
colon cancer cells: a) cell proliferation, b) cell cycle, and c) protein expression.  
 
 
The in vivo toxicity of O. cynarocephalum and C. ainetensis extracts was tested in Balb/c 
mice. Each extract was injected (i.p.) daily for 10 consecutive days and toxic signs such as 
weight  loss  and  death  were  monitored.  Both  extracts  were  not  toxic  to  the  animals  as  
evident by the normal weight gain and absence of death in all the groups (data not shown). 
Based on the toxicity data, the chemopreventive effect of the extract was studied in the 
well-established DMH model of colon cancer. This model induces colonic tumors of 
epithelial origin with similar histology, morphology, and anatomy to human colonic 
neoplasms (Maskens 1976). In addition, it offers multiple opportunities for assessment and 
intervention by the stepwise development of colorectal carcinogenesis from dysplastic 
aberrant crypt foci (ACF) (week 10) to adenomas (week 20) and adenocarcinomas (week 
30).  ACF  are  potential  markers  of  early  tumor  growth  and  are  considered  as  useful  
intermediate biomarkers for the modifying effect of certain natural or synthetic 
compounds on chemically induced carcinogenesis (Sengupta et al. 2004). 
 
Balb/c mice were treated as described in the materials and methods. At week 10, animals 
were selected randomly from each group, sacrificed and monitored for the presence of 
ACF. Following staining with Schiff's reagent, no ACF were observed in control treated 
groups (saline, plant extract) whereas in the DMH-treated group, all animals developed 
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ACF  (Fig.  3a,b).  Although  treatment  with  the  extracts  prior  to  DMH  did  not  affect  the  
average number of ACF, their average sizes were significantly inhibited (p < 0.05) as 
compared to DMH-treated group. At 20 and 30 weeks of treatment and using an optical 
microscope, significant inhibition was observed in DMH-extract treated mice. While at 
week 20, O. cynarocephalum and C. ainetensis induced 65% and 79% (p < 0.001) 
inhibition in extract-treated mice as compared to DMH-treated group, 63% and 73 % (p < 
0.0001) inhibition were observed at week 30, respectively (Fig. 3a,b). 
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Figure 3. Effect of crude extract of a) O. cynarocephalum and b) C. ainetensis, in vivo, on 
aberrant crypt foci (ACF, week 10), adenomas (week 20) and adenocarcinomas (week 30). 
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5.2. Bio-guided Fractionation of C. ainetensis and Isolation of    
       Salograviolide A (II) 
 
Based on the availability of sufficient plant material, only C. ainetensis was  selected  for  
the characterization of the active ingredient through bio-guided fractionation using the 
proliferation assay as an end point. 
The  extract  was  fractionated  into  4  fractions  (I.1,  I.2,  I.3,  and  I.4)  and  their  
antiproliferative effect was investigated on HCT-116 cells. Only fraction I.2 significantly 
inhibited the growth of these cells. Therefore, further fractionation was performed on the 
active fraction and a total of six subfractions (I.2.2-I.2.6) were obtained and consequently 
tested. The activity was retained in the I.2.2 subfraction, which induced significant growth 
inhibitory effects against colon cancer cells. The purification and identification of the I.2.2 
subfraction by solid phase extraction and spectroscopic techniques led to the isolation of 
Salograviolide A, which belongs to the guaianolide sesquiterpene lactones (Fig. 4a). The 
mechanism of action of Salograviolide A was further defined and compared to the effect 
observed with total extract using in vitro model. Salograviolide A inhibited the growth of 
a panel colon cancer cells in a concentration-dependent manner, and induced apoptotic 
cell death as evidenced by the TUNEL assay (Fig. 4b,c). Consequently, Salograviolide A, 
isolated from C. ainetensis was responsible,  at  least  in part,  for the activity of the crude 
biological extract. 
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Figure  4. a) Bio-guided fractionation of C. ainetensis. Effect of Salograviolide A on colon 
cancer cell proliferation (b) and apoptosis induction (c). 
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5.3. TQ mechanism of action (III)  
 
The present study (III) delineates the mechanism by which TQ induces its effect in colon 
cancer cells. The same in vitro techniques described previously for the evaluation of the 
anticancer activities used in the first two studies (I, II) were used in this study (III). Using 
the MTT-cytotox assay, TQ was found to inhibit the proliferation of a panel of colon 
cancer cells in a time and concentration-dependent manner (Fig. 5a) without inducing any 
toxicity to human normal intestinal cells (III). Investigations relating to the mechanism of 
action were carried out using DLD-1, a cell line that showed moderate sensitivity to TQ. A 
24h post-treatment significantly increased the percentage of cells observed in the preG1 
phase of the cell cycle (from 2.5 to 18.8%) in DLD-1 treated cells (Fig. 5b). The increase 
in the preG1 population was confirmed to be due to apoptosis by the M30 cytodeath 
antibody. The M30 cytodeath antibody recognizes a specific caspase cleavage site with 
cytokeratine 18 that is not detected in native cells. Using fluorescent microscopy the M30 
immunofluorescent images showed clear cytoplasmic signals for M30 antibody after TQ 
treatment, which confirmed apoptosis induction by TQ (Fig. 5c). 
Many chemotherapeutic agents induce their effect by ROS generation. As a quinone, TQ 
can undergo redox cycling in the presence of oxygen to produce ROS. Therefore, to 
confirm ROS generation in TQ-treated cells and to determine their involvement in TQ-
induced cell death, the antiproliferative effect of TQ was tested in DLD-1 cells in the 
presence and absence of the strong antioxidant NAC. NAC pretreatment completely 
reversed the inhibitory effects of TQ and cell viability was restored to 100 % (Fig. 5d). 
These findings correlated well with the ability of TQ to induce ROS, as measured by the 
extent of DCF fluorescence, an effect that was inhibited in the presence of NAC by 40%.  
 
TQ can also be a substrate for DT-diaphorase, an enzyme that catalyzes the two-electron 
reduction of quinones (oxidized form) to hydroquinones (reduced form) (Cullen et al. 
2003). HT-29 cells, known to express high levels of DT-diaphorase (Karczewski et  al. 
1999), were the least sensitive to TQ's antiproliferative effect and did not elicit any 
oxidant shift as compared to the controls. Therefore, to study the involvement of DT-
diaphorase in HT-29 cells resistance to TQ, the enzyme was inhibited by dicoumarol prior 
to TQ-treatment. As seen in Figure 4e, DT-diaphorase appeared to be partly responsible 
for the resistance of HT-29 cells whereby its inhibition sensitized the cells to TQ and 
reduced the IC50 from 95 to 63 µM (p < 0.05). These findings confirm that the mechanism 
of TQ-induced apoptotic cell death is via ROS production. 
 
ROS are known to activate members of the mitogen activated protein kinases (MAPK), so 
a thorough investigation was conducted to elucidate the link between ROS production by 
TQ and the subsequent activation of MAPK. The modulation of expression of ERK, JNK, 
and p38 (MAPK family) by TQ was studied in the presence and absence of NAC by 
western blot. As early as 15 min, a 12 and 14-fold induction was observed for p-ERK and 
p-JNK, respectively, in DLD-1 treated cells without any significant increase in total ERK 
and JNK. No changes in p-p38 and total p38 protein expression were observed in response 
to TQ. MAPK induction was confirmed to be due to ROS generation by TQ by the fact  
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that the induction observed in TQ-treated cells was completely abrogated in the presence 
of NAC. The role played by the MAPK in TQ-induced DLD-1 cell death was 
characterized by pre-treating the cells with the specific ERK 1/2 inhibitor PD98059 or 
with the specific JNK inhibitor SP600125. Data compiled from the proliferation assay, 
M30 cytodeath assay, caspase activation and DiOC6 assay proved a protective role for 
MAPK in TQ-induced cell death. Inhibition of both ERK and JNK pathways sensitized 
DLD-1 cells to TQ’s antiproliferative effect and potentiated TQ-induced apoptotic cell 
death (Fig. 5f). 
The proposed mechanism of TQ anti-tumor effect in colon cancer cells is as follows: 
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Figure  5.  TQ’s  effect  on  DLD-1  cell  proliferation  (a),  cell  cycle  (b),  apoptosis  (c),  and  
ROS generation (d). Sensitization of HT-29 cells to TQ’s effect by inhibiting DT-
diaphorase (e), and potentiation of TQ’s effect by MAPK inhibitors (f). 
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5.4. Impact of Protein Binding on TQ'S Analytical Detection and   
      Anticancer Activity (IV) 
 
The recovery of TQ (10 µg/ml) from spiked serum following SPE, LLE, and protein 
precipitation  prior  to  HPLC  analysis  was  less  than  5%.  The  use  of  different  ratios  of  
EtOAc  and  MeOH/ACN  for  extraction  and  protein  precipitation  did  not  improve  TQ  
recovery. However, the recovery from serum spiked with 100 µg/ml TQ improved to 65-
80 % with all the methods used. The ability to detect TQ at high concentration (100 
µg/ml) and not at a 10 times lower concentration implies that fresh serum has a capacity 
above which TQ can be detected. In addition, the fact that none of the organic solvents 
used during LLE or protein precipitation was effective in extracting TQ from serum 
implies that TQ might be covalently bound to serum components and that the non-
covalently bound TQ is below the detection limit. To investigate this assumption TQ 
binding to serum proteins was studied. Towards that end, 10 % and 100 % FBS were 
spiked with different concentrations of TQ (3.3 µg/ml, 6.6 µg/ml and 13.2 µg/ml) and the 
percentage of protein binding was determined, over 6 h, at different time intervals using 
the equation [% binding= (Total-free)/Total *100]. At all concentrations used, TQ binding 
in 10 % FBS was 86-93 % at 0 min and >96% after 30 min of incubation. In 100% FBS, 
however, 0 min of incubation resulted in more than 98% of binding. TQ binding to BSA 
and AGP, the most abundant protein in plasma, was determined and found to be 94.5% 
and 99.1%, respectively. 
 
The effect of protein binding on TQ’s anticancer activities was further investigated in 
DLD-1 human colon cancer cells. Pre-incubation of TQ with different FBS concentrations 
for  30  min  prior  to  addition  to  the  cells  resulted  in  a  significant  decrease  (p < 0.05) in 
TQ’s  anticancer  activities.  Since  TQ  was  incubated  with  FBS  prior  to  treatment,  we  
suggest that the observed loss of TQ’s activity comes from FBS component (s) on TQ 
rather than from FBS action on the cells.  
 
The protective effect exerted by FBS components on TQ-induced cell death was further 
explored by studying the effect of TQ binding to BSA and AGP. While incubation of TQ 
with increasing concentrations of BSA resulted in a concentration-dependent loss of its 
activity, pre-incubation with AGP prior to treatment did not alter its inhibitory effect at 
almost all the concentrations used. The loss of TQ activity was more pronounced in cells 
treated  with  TQ  +  240  µM  BSA  than  with  those  treated  with  TQ  +  40  %  FBS.  These  
results imply that TQ binds to proteins in serum where they may play a protective role and 
allow TQ to exert its effect while other(s) inactivate TQ.  
 
Further experiments were conducted in which TQ was incubated for 30 min with 60 µM 
BSA and for an additional 30 min with 2.5 µM AGP and vice versa. Interestingly, when 
TQ was pre-incubated with AGP prior to the addition of BSA, AGP protected TQ from 
binding  to  BSA  and  TQ's  effect  was  retained.  The  contrary  was  observed  when  the  
incubation order was reversed, whereby pre-incubation of TQ with BSA prior to AGP 
resulted in a significant loss of TQ's activity as compared to TQ alone. 
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TQ as a quinone can undergo facile adduction with electron-rich nucleophilic species such 
as activated amino, hydroxyl and thiol groups (Land et al. 2004; Li et al. 2005). BSA has 
a free cysteine on the position 34 of its amino acid sequence. AGP, on the other hand, has 
2 isoforms. Each has 2 disulfides bridges but the major difference is the presence of a free 
cysteine in position 147 in one isoform while the other has an arginine residue instead 
(Schmid et al. 1973). TQ binding to the free thiol group in BSA and AGP was further 
studied using sequences that were synthesized from regions surrounding the free thiol in 
BSA and AGP. Mass spectrometric analysis confirmed a covalent binding between TQ 
and sequences having a free thiol (Fig. 6). However, no binding was observed when TQ 
was incubated with the AGP isoform that has no free cysteine. 
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Figure 6. TQ covalent binding to BSA sequence on free thiol of Cyst-34. 
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6. DISCUSSION 
 
Medicinal plants have been used by diverse cultures around the world to promote health 
conditions and fight diseases. Due to the health benefits associated with the use of plants 
in folk medicine, the plants became an essential source for new chemical entities and the 
basis of many clinically approved drugs.  
 
Colorectal cancer (CRC) is one of the most devastating malignancies in the world. Yet the 
prolonged  series  of  neoplastic  events  required  for  clonal  expansion  from  the  time  of  
initiation until the beginning of invasive stage provides time and targets for preventive 
interventions. Many clinically used anticancer drugs that have provided hope for people 
with  cancers  resistant  to  conventional  treatment  are  based  on  plant  products.  Therefore,  
finding new plants/plant-derived compounds with medicinal properties holds great 
potential to prevent and cure this invasive disease. 
 
Cellular and molecular evidence obtained from the first two studies (I, II) indicate that 
crude plant extracts of O. cynarocephalum and C. ainetensis, plants indigenous to the 
Mediterranean region, inhibit the growth of colon cancer cells at concentrations that 
showed  no  apparent  toxicity  effects  against  normal  cells.  In vitro both extracts induced 
cell cycle arrest and apoptosis through modulation of the expression of specific 
components of the cell signaling pathways (p53, p21, cyclinB1, Bax and Bcl-2). The tumor 
suppressor protein p53 is known to play a key role in cell cycle arrest and apoptosis. Upon 
DNA damage, hypoxia or other stress stimuli, p53 induces the expression of p21, gadd45, 
and Bax, resulting in cell cycle arrest, DNA repair and apoptosis, respectively (Hedstrom 
et al. 2009; Kim et al. 2006; Taylor and Stark 2001). Furthermore, p53 by inhibiting the 
cyclin-dependent kinase (Cdc2) required for entering mitosis and by the repression of 
cyclin  B1 gene  plays  a  role  in  the  regulation  of  the  G2/M checkpoint (Sherr et al. 1995; 
Stewart et al. 1995; Taylor et al. 2001). The cyclin dependent kinase inhibitor p21 on the 
other hand, leads to cell cycle arrest at the G1 phase. Other mediators playing a 
fundamental role in apoptosis signaling are Bax and bcl-2. While the latter is an anti-
apoptotic protein that prevents the release of apoptotic factors such as cytochrome c and 
inhibits the activation of caspases, the former is a pro-apoptotic protein. When p53 
induces Bax, the balance between pro-apoptotic and anti-apoptotic proteins favors the 
former leading to the release of cytochrome c and promotes cell death. Correlation 
between cell cycle deregulation and carcinogenesis has been extensively studied. 
Therefore, inhibition of the cell cycle has been considered as a target for cancer treatment 
(Weinstein et al. 1997). 
 
The increase in p53 protein levels correlated well with the observed increase in the 
expression levels of p21 and Bax/bcl-2 ratio. In addition, apoptotic induction was further 
confirmed by the extract-induced inhibition of cyclin B1, the destruction of which is 
fundamental for mitotic exit and cytokinesis (Takizawa and Morgan 2000). 
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The tumor inhibitory effect of O. cynarocephalum and C. ainetensis extracts were further 
investigated in vivo. Since cancer intervention can take many decades and harmful effects 
must be minimal, toxicity or adverse side effects must be evaluated prior to long-term 
treatment.  The  results  show  that  administration  of  the  extracts  for  10  consecutive  days  
have  no  effect  on  mice  mean body weight  nor  have  resulted  in  any  death.  Based  on  the  
toxicity  data,  the  tumor  inhibitory  effect  of  the  extracts  was  carried  on  using  the  DMH  
model of colon cancer.  
 
Tumor development is divided into stages of initiation, promotion, and progression. 
While in the initiation phase irreversible genetic changes, such as mutations take place in 
normal cells, promotion of initiated cells to pre-neoplastic lesions is governed by 
epigenetic and potentially reversible events. During the progression phase additional DNA 
mutations and epigenetic changes play a major role in driving mitogenesis and apoptosis 
resistance to eventual neoplasia (Trosko 2001).  
 
Depending on the timing of anticarcinogenic actions, chemopreventive agents can be 
classified into those that inhibit tumor initiation, and those that block tumor promotion and 
progression (Wali et al. 2002). The results in study I and II show that both extracts did not 
decrease the average numbers of ACF (week 10), potential markers of tumor growth, 
however they significantly (p < 0.001) inhibited tumor formation at weeks 20 and 30. 
 
The inhibitory effects of the extracts on tumor formation and not on ACF development 
suggest that the two extracts act during the promotion and progression stages and not 
during the initiation stage of colorectal carcinogenesis. A similar effect was observed with 
rofecoxib, a highly selective inhibitor of cyclooxygenase-2 shown to inhibit the later 
stages of DMH-induced colon carcinogenesis in Wistar rats (Perse et al. 2005).  
 
In studies II and III, the inhibitory effects of two plant-based products, Salograviolide A 
and TQ, have been investigated in vitro. Salograviolide A, isolated through bio-guided 
fractionation of C. ainetensis crude extract, has been found to induce apoptosis in colon 
cancer cells as the mother crude extract (II). While Salograviolide A, isolated from other 
Centaurea plants, was shown to possess antifungal activities (Vajs et al. 1999), no other 
activities have been reported so far. Therefore, the anti colon-tumor activities of 
Salograviolide A reported in this study (II) are new activities identified for this molecule.  
 
TQ, the active constituent of N. sativa, has been found to induce apoptotic cell death as 
well (III). The fact that the further studies have been conducted on TQ is based on three 
facts: 1) TQ has already potent in vitro/in vivo activities and lacks toxicity, 2) in many 
countries the plant is incorporated into diets and everyday lifestyles to improve health 
conditions, and 3) TQ is readily obtained from several companies, bypassing hence the 
difficulties of plant supply and extraction procedures. 
 
Although in vitro and in vivo studies  show  that  TQ  is  a  potent  anticancer  agent,  its  
mechanism of action is not yet fully defined. Therefore, to decipher the exact mechanism 
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of TQ action, a wide variety of molecular and cellular biology experiments have been 
performed. TQ, as a quinone, is known to undergo one or two electrons reduction by 
cellular reductases. While one electron reduction results in the formation of semiquinones, 
two electron reductions produce hydroquinones. ROS are the by-product of the reaction of 
semiquinones with molecular oxygen. Hydroquinones formed by DT-diaphorase action 
are of three types, 1) redox-stable hydroquinones, 2) redox-labile hydroquinones that 
subsequently auto-oxidize with formation of ROS and 3) hydroquinones that readily 
rearrange to potent electrophiles participating in bioalkylation reactions (Cadenas 1995). 
The properties of the hydroquinone generated by DT-diaphorase determine whether this 
reduction leads to the activation or deactivation of quinones. Several reports attribute the 
potency of TQ to its antioxidant properties (Badary et al. 2003; Brewer et al. 2006; Nagi 
and Mansour 2000; Richards et  al. 2006; Tan et  al. 2006). In study III, however, TQ-
induced apoptotic cell death has been confirmed to be mediated by ROS resulting from its 
one electron reduction and that its two electrons reduction by DT-diaphorase leads to its 
detoxification. 
 
The pro-oxidant effects of TQ are in accordance with studies showing that TQ is involved 
in mitochondrial ROS generation in human osteosarcoma and leukemia Jurkat cells 
(Alhosin et al. 2010; Roepke et al. 2007). The pro-oxidant/antioxidant activities of TQ 
depend on the milieu where it is present.  
 
Oxidative stress is known to activate the MAPK family and therefore might contribute to 
influencing survival (Matsuzawa and Ichijo 2005; Navarro et  al. 2006). MAPK family 
consists of three subfamilies: extracellular signal-regulated kinase (ERK), c-jun N-
terminal kinase (JNK), and p38 MAP kinase that play a key role in the regulation of many 
cellular processes, such as cell growth and proliferation, differentiation, and apoptosis 
(Kyosseva 2004). Many studies have been made to link MAPK activation and apoptosis 
induction during stress conditions. While the ERK pathway usually confers a survival 
signal, JNK and p38 activation are associated with pro-apoptotic signals (Brenner et al. 
1997; Guyton et al. 1996). JNK and ERK, but not p38 kinases, were activated 
significantly in the presence of TQ (III). The activation of ERK and JNK has been shown 
to play a survival role whereby inhibition of the ERK pathway by PD98059 and JNK 
pathway by SP600125 potentiated apoptosis induction by TQ (III). Therefore to further 
improve the anti-tumor activities of TQ, combinatorial treatment with a kinase inhibitor 
such as sorafenib could be used. In fact, sorafenib has successfully improved the 
anticancer activity of doxorubicin and irinotecan.  
 
Despite the considerable data reported for the biological activities of TQ against cancer 
and inflammation, no studies have dealt with its pharmacokinetic profile. This is probably 
due to the absence of analytical methods for the isolation and quantification of TQ from 
blood/plasma, a prerequisite for the determination of its pharmacologically achievable 
doses and clearance from blood. However, only two HPLC methods have been reported 
for its quantification from black seed oil (Aboul-Enein and Abou-Basha 1995; Ghosheh et 
al. 1999). The absence of analytical methods for TQ detection from serum might be the 
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reason for the absence of data describing its pharmacokinetic profile, a prerequisite for its 
further clinical evaluation. As TQ belongs to the quinone family, known to have 
electrophilic property, it has the ability to undergo nucleophilic attack as activated amino, 
hydroxyl and thiol groups (Land et al. 2004; Li et al. 2005), which may lead to 
detoxification or enhanced toxicity. In biological systems, such nucleophiles may be found 
as reactive side-groups of lysine, serine and cysteine (Magee 2000). The ability of TQ to 
bind covalently to proteins might influence its analytical detection for irreversible binding 
might result in a decrease in its free concentration to a level that is below the detection 
limit. In study IV, spiked serum subjected to several sample cleanup procedures (SPE, 
LLE, protein precipitation) prior to HPLC analysis,  resulted in low recovery < 5% when 
10 µg/ml of TQ was used and increased to 72 % when the extremely high concentration of 
100 µg/ml was used. The results show that TQ extraction and quantification from spiked 
serum is not possible using conventional analytical methods since high recovery is 
observed with a concentration that is not reflective of the real pharmacological achievable 
dose. 
 
The proposed explanation is that TQ may undergo reversible and irreversible binding to 
serum components. When serum is spiked with low concentration of TQ, many 
irreversible binding sites are available and the free and reversibly bound TQ is below the 
detection limit thus explaining the low recovery. On the other hand, when higher 
concentrations of TQ were used, all the irreversible binding sites were occupied and the 
free TQ was easily extracted and detected by the proposed method. To prove this 
hypothesis, a thorough investigation was performed. Our findings show that the extensive 
binding of TQ to serum proteins (> 90%) may play a major role in the observed low 
recovery and provide evidence for the absence of conventional analytical methods for TQ.   
 
The study of the binding effect on TQ-induced cell death in colon cancer shows that TQ 
binding to BSA resulted in its inactivation while its binding to AGP maintains its activity. 
The fact that TQ extensive binding to AGP did not alter its inhibitory effect suggests that 
in serum there is a competition in the binding of TQ to different plasma components. Mass 
spectrometric analysis shows that TQ binds covalently to the free thiol on the 34th position 
of the amino acid sequence of BSA. Serum contains many components that have free thiol 
groups to which TQ can be bind covalently confirming again the difficulties in detecting 
TQ in serum. Our data on TQ covalent binding contradicts a recent study published by 
Lupidi G et al.,  where they showed that TQ binds to the site I  of human serum albumin 
(HSA) by a hydrophobic interaction (Lupidi et al. 2010). The discrepancy between our 
results using BSA and the results reported by Lupidi et al. on TQ binding to HSA could be 
due to differences in species and analytical techniques used. The effect of serum 
components on TQ’s activity resembles that observed with ET-743, a novel marine 
antitumor compound against soft tissue sarcomas and ovarian cancer, which is in phase I 
and II clinical studies (Tognon et al. 2004). ET-742’s antitumor activity was lost when the 
percentage of FBS was increased; however, the activity was restored when the compound 
was first prepared in HSA then diluted with FBS, confirming thus the protective effect of 
HSA on the drug against the inactivation exerted by FBS components (Tognon et al. 
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2004). The protection offered by HSA is similar to the effect offered by AGP prior to the 
addition of BSA. Our result on the loss of TQ activity when TQ is bound to serum 
components correlate well with a new study showing that encapsulation of TQ in 
nanoparticles improves the antitumor effect of TQ against colon, breast, prostate, and 
myeloma cancer in vitro (Ravindran et al. 2010). The nanoparticles protected TQ from 
such an inhibitory effect and increased TQ potency against cancer cells. TQ non-covalent 
and covalent binding to plasma proteins can cause problems in its detection thus limiting 
the use of conventional methods for determining its bioavailability. In addition to the 
effect on detection, the binding of drugs to plasma and tissue proteins can affect the drug’s 
ADME  and  can  result  in  adverse  side  effects.  The  ability  of  TQ  to  bind  covalently  to  
proteins with free thiol raises concerns about its long term use. While the covalent binding 
and thus the decrease in the available free drug might result in instant absence of toxicity, 
consecutive administration of the drug could be responsible in drug-induced toxic side 
effects. This can be explained by the fact that once, in the presence of quinones, the 
plasma free thiols and cellular GSH are depleted, cellular SH-dependent proteins can be 
alkylated thereby causing irreversible changes and cell death (Buffinton et  al. 1989; 
Jakoby and Ziegler 1990). Eventhough short term in vivo toxicity studies has shown that 
TQ is not toxic (Gali-Muhtaseb et al. 2008a), long term toxicity studies should be 
performed to confirm its safe use.   
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7. CONCLUSIONS 
 
The increase in the incidence of CRC along with the undesirable side effects observed 
with the available chemopreventive drugs urges the discovery of new agents from natural 
sources. The goal of prevention is to decrease morbidity and mortality from CRC. To 
achieve this goal, it is important to delay the progression of early neoplasia or reverse/ 
inhibit the development of invasive cancer. 
 
Strong side effects are usually associated with most of the known chemotherapeutic drugs. 
Interestingly,  in  studies  I,  II,  and  III  the  plants  (O. cynarocephalum, C. ainetensis) and 
plant-based products (Salograviolide A and TQ) show high selectivity against cancer cells 
with no apparent toxic effects on normal cells. This differential effect makes the 
aforementioned natural products potentially harmless chemopreventive agents against 
colon cancer development (I, II, III).  
 
The results of study III and IV cover the lack of useful information for the better 
understanding of the PK/PD profile of TQ, a well-established anticancer plant derived-
compound. In study III, early events of TQ's induced apoptotic cell death are defined. 
Using a radical scavenger and several inhibitors the mechanism is identified as follows: 
TQ, absorbed by the cells as early as 15 min, undergoes redox-cycling and generates ROS. 
ROS  mediate  apoptosis  and  result  in  the  activation  of  p-ERK  and  p-JNK,  which  are  
known to play a protective role against TQ-induced cell death (III). In study (IV) 
evidences prove that the absence of analytical methods for TQ detection from blood/serum 
and therefore pharmacokinetic studies are due to extensive protein binding, especially 
covalent binding. Even though many reports show that TQ is active in vitro and in vivo, 
the actual behavior of TQ in plasma remains an unanswered question that merits further 
investigation. 
 
This thesis confirms the usefulness of two endemic Lebenase plants used in folk medicine, 
identifies a new compound with anticancer activity and enhances the understanding of the 
pharmaceutical properties of the promising anticancer compound TQ.  
 
Based on the reported data in this study there is a need to 1) further fractionate O. 
cynarocephalum to isolate the active constituent (s) responsible for the plant’s in vitro and 
in vivo activity, 2) develop a method for Salograviolide A extraction and quantification 
from blood/serum for future pharmacokinetic studies, and 3) synthesize radiolabeled or 
isotopically labeled TQ for clarifying its pharmacokinetic properties, required for its future 
clinical development. 
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